Please login to the form below

Not currently logged in

Novartis to buy Ebewe Pharma generics unit

Novartis has signed an agreement to purchase Ebewe Pharma's speciality generic injectables business for €925m

Novartis has signed an agreement to purchase Ebewe Pharma's speciality generic injectables business for €925m.

The deal will see Sandoz - Novartis' generic division and the second-largest generics company in the world - expand its generic oncology portfolio considerably.

"The addition of Ebewe Pharma's leading portfolio of oncology medicines fits our strategy and improves our ability to help cancer patients around the world by providing easier access to therapies. These medicines will remain the backbone of multi-drug treatments in the fight against cancer, one of the world's leading causes of death," said Dr Daniel Vasella, chairman and CEO of Novartis. "Ebewe Pharma will further strengthen our pipeline with many planned near-term launches."

Ebewe Pharma, an Austrian company, has built a lot of its success by developing value-added products such as advanced delivery devices and innovative package (eg Onco-Safe), rather than just pure generic versions of branded equivalents.

Sandoz plans to form a new global centre of excellence, based in Austria and led by Friedrich Hillebrand. The business will centre around the company's new acquisition and will aim to capitalise on Ebewe's previous success in hospital marketing and string customer partnerships.

The €925m cash deal, expected to be completed in 2009, will include the production site in Austria along with research, development and manufacturing assets of the business. It does not include Ebewe Pharma's injectable neurological products business. 

21st May 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...